101 related articles for article (PubMed ID: 8241794)
1. Graft-versus-host disease in bone marrow transplantation: experimental, laboratory, and clinical contributions of the last few years.
Kelemen E; Szebeni J; Petrányi GG
Int Arch Allergy Immunol; 1993; 102(4):309-20. PubMed ID: 8241794
[TBL] [Abstract][Full Text] [Related]
2. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
3. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant.
Vogelsang GB; Lee L; Bensen-Kennedy DM
Annu Rev Med; 2003; 54():29-52. PubMed ID: 12359826
[TBL] [Abstract][Full Text] [Related]
6. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
Liem LM; van Noort JT; Goulmy E
Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to the control of graft versus host disease.
Sykes M
Curr Opin Immunol; 1993 Oct; 5(5):774-81. PubMed ID: 8240740
[TBL] [Abstract][Full Text] [Related]
8. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
10. Acute graft-versus-host disease does not require alloantigen expression on host epithelium.
Teshima T; Ordemann R; Reddy P; Gagin S; Liu C; Cooke KR; Ferrara JL
Nat Med; 2002 Jun; 8(6):575-81. PubMed ID: 12042807
[TBL] [Abstract][Full Text] [Related]
11. Preventive effect of ultraviolet radiation on murine chronic sclerodermatous graft-versus-host disease.
Mermet I; Kleinclauss F; Marandin A; Guérrini JS; Angonin R; Tiberghien P; Saas P; Aubin F
Transplantation; 2007 Dec; 84(12):1696-700. PubMed ID: 18165783
[TBL] [Abstract][Full Text] [Related]
12. What determines who develops graft-versus-host disease: the graft or the host (or both)?
Gale RP; Horowitz MM; Butturini A; Barrett AJ; Kolb HJ
Bone Marrow Transplant; 1992 Aug; 10(2):99-102. PubMed ID: 1525613
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
14. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
[TBL] [Abstract][Full Text] [Related]
15. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
17. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
Truitt RL; Atasoylu AA
Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
[TBL] [Abstract][Full Text] [Related]
18. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
19. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
[TBL] [Abstract][Full Text] [Related]
20. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
